Pfizer says COVID-19 vaccine for 5-to-11-year-olds offers ‘robust’ immunity

Dr. Sunanda Gaur says results show the lower vaccine dosage used for kids caused fewer side effects

Nine-year-old Justin Do got two shots this summer as one of 70 kids who took part in Pfizer’s apparently successful COVID-19 vaccine trial for 5-to-11-year-olds at Rutgers. Justin’s parents enrolled him in the trial that nationally included almost 2,270 kids. About two-thirds got a couple doses of vaccine — 10 micrograms —  and about one-third the adult dose. The rest got a placebo.

On Monday, Pfizer-BioNTech announced that  results suggest “… the vaccine was safe, well tolerated and showed robust neutralizing antibody responses.” Justin’s dad told NJ Spotlight News on the phone, “I’m not surprised at all. We knew what we were getting into, because we knew that the science works. I’m very happy that they can confirm the expectations.”

Pfizer-BioNTech will ask the FDA for Emergency Use Authorization “as soon as possible.”

We’re in this together
For a better-informed future. Support our nonprofit newsroom.
Donate to NJ Spotlight